AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 212 min read$IART

What Integra LifeSciences (IART) Said on Its Q3 Earnings Call

Integra LifeSciences (IART) reported Q3 revenue of $304.1M, with neurosurgery growing 6.5% organically. Tissue Reconstruction revenue declined 2.2% to $107.1M. The company reaffirmed its full-year revenue outlook of $1.634B-$1.654B but reduced the midpoint by $30M. It expects 2027 revenue and EPS growth, supported by SurgiMend relaunch and PriMatrix momentum. Net debt was $1.5B at quarter-end, with leverage at 3.8x.

Original reporting
finance.yahoo.com
Published Oct 21, 2026, 4:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 4:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
What Integra LifeSciences (IART) Said on Its Q3 Earnings Call — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The lowered guidance and added financing costs create near‑term downside risk, but 2027 growth initiatives may offset long‑term concerns.

02

Market read

First‑report earnings and financing disclosure for a mid‑cap med‑tech firm, likely to move the stock today.

03

What to watch

Potential upside from upcoming SurgiMend label expansion and international sales momentum.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Integra LifeSciences (NASDAQ:IART) provides neurosurgery and tissue reconstruction products. The Q3 earnings call highlighted mixed segment performance and a recent $2.1B refinancing.

Company-level read

Ticker impact

$IARTBearishHigh confidence
Context

Integra LifeSciences reported Q3 results, lowered full-year revenue guidance by $30M and disclosed a $2.1B refinancing that adds $8M interest expense in Q4.

Expected impact

likely downside as market prices in lower revenue outlook and added interest expense

Evidence & confidence

The earnings call disclosed fresh guidance and financing details that were not previously public, providing a clear catalyst for price movement.

Market effects

Sector

Medical device sector may see modest pressure as Integra's guidance downgrade signals demand softness in tissue reconstruction.

Regional

U.S. healthcare stocks could face slight pullback in the short term.

Global

Limited to U.S. listed med‑tech equities; no broader macro impact.

Counterpoint

What could challenge this read

If the refinancing improves balance sheet flexibility, the stock could rebound on longer‑term growth prospects.

Key entities

  • Company
    Integra LifeSciences

    Medical device manufacturer reporting Q3 results and guidance.

Read at source← All news

StoryIntegra LifeSciences reports Q3 2026 results, cites $7 M flood hit, completes $2.1 B refinancing and trims Q4 outlook

Also covered by

6 outlets

Related articles

OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min
OCT 21
$IARTHighAI 8/10

Integra (IART) Q3 2026 Earnings Call Transcript

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

finance.yahoo.com3 min
OCT 21
$IARTHigh

Integra Life falls as tissue reconstruction woes add to flooding worries in Q3

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

tradingview.com2 min
OCT 21
Med

Integra LifeSciences Holdings Corporation Q3 2026 Earnings Call Summary

Integra LifeSciences reported Q3 2026 earnings, citing a $7M revenue hit from Cincinnati flooding. Neurosurgery grew 6.5% organically, offsetting weaker segments. Tissue Reconstruction showed mixed results. The company refinanced $2.1B in debt. Management expects 2027 revenue to be impacted by $15M-$20M in Q1 and Q2 due to ongoing disruption. Earnings growth is projected to be supported by cost savings and a SurgiMend relaunch.

finance.yahoo.com2 min
OCT 21
$IARTMed

Why Integra LifeSciences (IART) stock is falling today

Integra LifeSciences (IART) shares fell 7.3% after reporting Q3 revenue of $411.2M, meeting expectations, and adjusted EPS of $0.59, beating estimates. The company cited plant flooding and operational disruptions, projecting Q4 revenue of $413M-$433M, below analyst estimates of $433.2M. Rising borrowing costs also weighed on investor sentiment.

financialcontent.com2 min